A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO EVALUATE THE
EFFICACY, SAFETY, AND TOLERABILITY OF REMIBRUTINIB IN PATIENTS WITH GENERALIZED
MYASTHENIA GRAVIS, FOLLOWED BY AN OPEN-LABEL EXTENSION PHASE
- Registry ID
- CLOU064O12301
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- NOVARTIS PHARMACEUTICALS CANADA INC
- Start date
- 2025-12-18
- Last update
- 2025-02-07
Conditions
Related clinical trials
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT PARTICIPANTS WITH OCULAR MYASTHENIA GRAVIS
- A RANDOMIZED, DOUBLE-BLINDED, PLACEBOCONTROLLED, PHASE 3, PARALLEL-GROUP DESIGN STUDY EVALUATING THE EFFICACY AND
SAFETY OF EFGARTIGIMOD PH20 SC ADMINISTERED BY PREFILLED SYRINGE IN ADULT
PARTICIPANTS WITH OCULAR MYASTHENIA GRAVIS
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, 3-PERIOD STUDY TO
ASSESS THE EFFICACY AND SAFETY OF A NEW FORMULATION OF ORAL CLADRIBINE COMPARED WITH
PLACEBO IN PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS
- A LONG-TERM, SINGLE-ARM, OPEN-LABEL, MULTICENTER, FOLLOW-ON TRIAL OF ARGX- 113-2006 TO EVALUATE SAFETY OF EFGARTIGIMOD ADMINISTERED INTRAVENOUSLY IN CHILDREN WITH GENERALIZED MYASTHENIA GRAVIS
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ALXN1720 IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
- A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF TAK-079 IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
View on source registry